7,8-Dihydroxyflavone

1. What conditions has 7,8-Dihydroxyflavone been studied for?

• Depression / inflammation-related depression (preclinical): Discussed as a TrkB agonist relevant to inflammation-induced depression mechanisms involving altered BDNF–TrkB signaling (overview/review abstract) and tested in mouse depression models (social defeat stress; tail suspension/forced swim; sucrose preference).

• Stress-related learning and fear/extinction (preclinical): Studied for effects on emotional memory, fear acquisition, and fear extinction, including stress-induced extinction deficits in mice.

• Alzheimer’s disease (AD) (preclinical): Tested in vitro against Aβ toxicity and in vivo in 5XFAD transgenic mice for synapses, pathology, and memory.

• Traumatic brain injury (TBI) (preclinical): Reviewed as a BDNF-mimetic TrkB agonist with potential neuroprotection/neuroregeneration after TBI.

• Peripheral nerve injury / long-gap nerve defects (preclinical): Used as a sustained-release prodrug nanoassembly in a 3D-printed hydrogel conduit in a rat sciatic nerve defect model.

• Insomnia mechanism validation (preclinical): Used as a TrkB agonist to confirm that activating BDNF/TrkB signaling contributes to a traditional formula’s anti-insomnia effects in a rat model.

• Antibiotic adjuvant use (infectious disease pharmacology, preclinical/in vitro): Identified in a screening platform as a catechol-type flavonoid that potentiates colistin activity by disrupting bacterial iron homeostasis.

• General “BDNF/TrkB-deficiency–related disorders” (review-level): A review abstract states it has shown efficacy across “various animal disease models” related to deficient BDNF signaling, but specific additional conditions are not enumerated in the provided text.

2. Does it work in treating those conditions? Summarize the evidence.

• Depression-like behavior in mice: In the social defeat stress model, a single dose of 7,8-DHF reduced depression-like behaviors (reduced immobility in tail suspension/forced swim; improved sucrose preference at 1 and 3 days). However, its effect was not detectable at 7 days, unlike ketamine. Biochemically, ketamine (but not 7,8-DHF) reversed reduced BDNF and PSD-95 in key regions 8 days after dosing, suggesting 7,8-DHF’s antidepressant-like effects may be shorter-lived in that paradigm.

• Fear learning/extinction (mouse emotional memory): Systemic 7,8-DHF (5 mg/kg i.p.) activated TrkB receptors in the amygdala and enhanced fear acquisition and extinction. It also appeared to rescue an extinction deficit in mice with prior immobilization stress. This supports central target engagement (TrkB activation) and behavioral effects in BDNF-dependent learning paradigms.

• Alzheimer’s disease models: In primary neurons, 7,8-DHF protected against Aβ-induced toxicity and promoted dendrite branching/synaptogenesis. In 5XFAD mice, chronic oral 7,8-DHF activated TrkB signaling, was reported to prevent Aβ deposition, inhibit hippocampal synapse loss, restore synapse number and synaptic plasticity, and prevent memory deficits. These are strong preclinical signals, but they remain animal-model evidence (not human clinical outcomes).

• Improved exposure via prodrug (R13) in AD mice: Because 7,8-DHF itself has “modest oral bioavailability” and only a “moderate PK profile,” a prodrug (R13) was developed that “prominently” improved PK. Chronic oral R13 activated TrkB signaling and improved AD-like outcomes in 5XFAD mice (reduced Aβ deposition; inhibited pathological cleavage of APP and Tau by AEP; reduced synapse loss; improved memory deficits dose-dependently). This supports the concept that TrkB agonism can be beneficial in this model and highlights formulation/PK as a key determinant of in vivo effect.

• TBI: The provided TBI abstract is a review summarizing that 7,8-DHF has shown “similar effects as BDNF” in promoting neuronal survival and regeneration following TBI, and emphasizes BBB penetration and longer half-life vs BDNF. However, the abstract does not provide specific experimental outcomes or effect sizes.

• Peripheral nerve injury (rat sciatic nerve defect): A drug-releasing conduit that sustainedly released 7,8-DHF was associated with improved electrophysiological, morphological, and histological outcomes (axon regeneration, remyelination, functional recovery) in a 12 mm defect model. This suggests benefit in a localized delivery/tissue engineering context, but it is not evidence for oral supplementation in humans.

• Insomnia (mechanism confirmation): In a rat insomnia model, 7,8-DHF was used to confirm that activating BDNF/TrkB signaling can ameliorate insomnia-related outcomes in that experimental context. The abstract frames 7,8-DHF as supporting the mechanism (TrkB activation) rather than as a standalone insomnia therapy with fully described outcomes.

• Antibiotic adjuvant (colistin potentiation): In a host-mimicking screening platform, 7,8-DHF “prominently” potentiated colistin efficacy. Mechanistically, it converted ferric iron to ferrous iron, disrupting bacterial iron homeostasis and altering membrane charge via interference with a two-component system. This is promising as an adjuvant concept, but it is not clinical evidence and is not a “treatment” effect in humans.

Overall, the abstracts provide consistent preclinical evidence that 7,8-DHF engages TrkB signaling in the brain and can improve outcomes in multiple animal models. However, the provided material does not include human clinical trials, so effectiveness for human treatment remains uncertain.

3. What health benefits does it have?

• Neurotrophic/neuronal support via TrkB activation: Multiple abstracts describe 7,8-DHF as a small-molecule TrkB agonist that mimics BDNF, inducing TrkB dimerization and downstream signaling, with reported BBB penetration and oral bioactivity (review abstract).

• Synaptic and cognitive benefits in AD models: In 5XFAD mice, chronic oral 7,8-DHF was reported to preserve hippocampal synapses, restore synaptic plasticity, and prevent memory deficits; in vitro it promoted dendrite branching and synaptogenesis and protected neurons from Aβ toxicity.

• Antidepressant-like behavioral effects (short-term) in mice: In social defeat stress, 7,8-DHF improved behavioral readouts (immobility and sucrose preference) for up to 3 days after a single dose.

• Modulation of fear learning and extinction: 7,8-DHF activated amygdala TrkB and enhanced both acquisition and extinction of conditioned fear, and may improve extinction deficits after stress exposure (mouse data).

• Neuroprotection/neuroregeneration potential after injury: A TBI-focused review suggests 7,8-DHF can promote neuronal survival and regeneration following TBI, with practical advantages over BDNF (BBB penetration, longer half-life).

• Peripheral nerve regeneration support (localized delivery): Sustained release from a hydrogel conduit was associated with axon regeneration, remyelination, and functional recovery in a rat long-gap nerve injury model.

• Potential antibiotic-sparing/adjuvant benefit: 7,8-DHF potentiated colistin activity in a screening platform by disrupting bacterial iron homeostasis (mechanistic antimicrobial adjuvant concept).

4. Does it have any downsides or side effects?

• Limited durability in at least one depression model: In social defeat stress, antidepressant-like effects of 7,8-DHF were present at 1–3 days but not detectable at 7 days after a single dose, unlike ketamine. This suggests potential limitations in sustained efficacy (at least with that dosing paradigm and model).

• Pharmacokinetic limitations (oral bioavailability/PK): One abstract explicitly states 7,8-DHF has “modest oral bioavailability” and a “moderate PK profile,” motivating development of the prodrug R13 to increase exposure and brain levels. This is a practical downside for oral use and may affect real-world effectiveness.

• Potential to alter fear learning: In mice, 7,8-DHF enhanced both fear acquisition and extinction. While enhanced extinction could be beneficial in some contexts, enhanced fear acquisition could be undesirable depending on timing/context (e.g., around trauma exposure). The abstract does not report adverse outcomes, but it indicates bidirectional effects on emotional learning.

• Safety/side effects not characterized in the provided abstracts: None of the included abstracts provide systematic toxicology, adverse event rates, organ safety signals, or human tolerability data for 7,8-DHF. Therefore, side effects in humans cannot be concluded from this set of abstracts.

• Mechanistic caution (non-human contexts): The antibiotic-adjuvant mechanism involves redox/iron chemistry (ferric-to-ferrous conversion) in bacteria; the abstracts do not address whether similar chemistry could have off-target consequences in host tissues at relevant exposures.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic analyses (e.g., genotype-stratified responses, TrkB/NTRK2 variants, BDNF Val66Met, metabolism-related polymorphisms such as UGT/CYP variants) for 7,8-DHF.

• No direct evidence in these abstracts that any specific genetic variant makes 7,8-DHF more beneficial or more harmful.

• Indirect relevance only: Because 7,8-DHF targets the BDNF–TrkB pathway, variants affecting BDNF or TrkB signaling could plausibly influence response, but that is a hypothesis not tested in the provided material.

References

1. Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets.
   Ji-Chun Zhang, Wei Yao, Kenji Hashimoto (2016) - Current neuropharmacology
2. Natural flavonoids disrupt bacterial iron homeostasis to potentiate colistin efficacy.
   Zi-Xing Zhong, Shuang Zhou, Yu-Jiao Liang, Yi-Yang Wei, Yan Li, Teng-Fei Long, Qian He, Meng-Yuan Li, Yu-Feng Zhou, Yang Yu, Liang-Xing Fang, Xiao-Ping Liao, Barry N Kreiswirth, Liang Chen, Hao Ren, Ya-Hong Liu, Jian Sun (2023) - Science advances
3. 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease.
   Zhentao Zhang, Xia Liu, Jason P Schroeder, Chi-Bun Chan, Mingke Song, Shan Ping Yu, David Weinshenker, Keqiang Ye (2014) - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
4. Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury.
   Mary Wurzelmann, Jennifer Romeika, Dong Sun (2017) - Neural regeneration research
5. The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease.
   Chun Chen, Zhihao Wang, Zhentao Zhang, Xia Liu, Seong Su Kang, Ying Zhang, Keqiang Ye (2018) - Proceedings of the National Academy of Sciences of the United States of America
6. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression.
   Ji-chun Zhang, Wei Yao, Chao Dong, Chun Yang, Qian Ren, Min Ma, Mei Han, Kenji Hashimoto (2015) - Psychopharmacology
7. Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning.
   Raul Andero, Scott A Heldt, Keqiang Ye, Xia Liu, Antonio Armario, Kerry J Ressler (2011) - The American journal of psychiatry
8. 7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders.
   Chaoyang Liu, Chi Bun Chan, Keqiang Ye (2016) - Translational neurodegeneration
9. 3D printed elastic hydrogel conduits with 7,8-dihydroxyflavone release for peripheral nerve repair.
   Wenbi Wu, Yinchu Dong, Haofan Liu, Xuebing Jiang, Ling Yang, Jing Luo, Yu Hu, Maling Gou (2023) - Materials today. Bio
10. Huanglian Wendan Decoction Improves Insomnia in Rats by Regulating BDNF/TrkB Signaling Pathway Through Gut Microbiota-Mediated SCFAs and Affecting Microglia Polarization.
    Min Shi, Jie Yang, Ying Liu, Huan Zhao, Man Li, Dongdong Yang, Quan Xie (2025) - Molecular neurobiology
11. Astragaloside IV mediates radiation-induced neuronal damage through activation of BDNF-TrkB signaling.
    Xin Liu, Yanping Ding, Chenxin Jiang, Yuanyuan Xin, Xin Ma, Min Xu, Qianhao Wang, Boru Hou, Yingdong Li, Shengxiang Zhang, Baoping Shao (2024) - Phytomedicine : international journal of phytotherapy and phytopharmacology
12. A rare olive compound oleacein functions as a TrkB agonist and mitigates neuroinflammation both in vitro and in vivo.
    Daiki Wakasugi, Shinji Kondo, Farhana Ferdousi, Seiya Mizuno, Akira Yada, Kenichi Tominaga, Satoru Takahashi, Hiroko Isoda (2024) - Cell communication and signaling : CCS
13. Antioxidant activity of 7,8-dihydroxyflavone provides neuroprotection against glutamate-induced toxicity.
    Jing Chen, Kao-Wei Chua, Chu C Chua, Hailong Yu, Aijie Pei, Balvin H L Chua, Ronald C Hamdy, Xingshun Xu, Chun-Feng Liu (2011) - Neuroscience letters
14. 7,8-Dihydroxyflavone and Neuropsychiatric Disorders: A Translational Perspective from the Mechanism to Drug Development.
    Shaojie Yang, Guoqi Zhu (2022) - Current neuropharmacology
15. Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders.
    Miora Rakotoarisoa, Angelina Angelova (2018) - Medicines (Basel, Switzerland)
16. Treatment with the flavonoid 7,8-Dihydroxyflavone: a promising strategy for a constellation of body and brain disorders.
    Marco Emili, Sandra Guidi, Beatrice Uguagliati, Andrea Giacomini, Renata Bartesaghi, Fiorenza Stagni (2022) - Critical reviews in food science and nutrition
17. Design and Molecular dynamic Investigations of 7,8-Dihydroxyflavone Derivatives as Potential Neuroprotective Agents Against Alpha-synuclein.
    Thangavel Mohankumar, Vivek Chandramohan, Haralur Shankaraiah Lalithamba, Richard L Jayaraj, Poomani Kumaradhas, Magudeeswaran Sivanandam, Govindasamy Hunday, Rajendran Vijayakumar, Rangasamy Balakrishnan, Dharmar Manimaran, Namasivayam Elangovan (2020) - Scientific reports
18. 7,8-Dihydroxyflavone alleviates cardiac fibrosis by restoring circadian signals via downregulating Bmal1/Akt pathway.
    Peng-Zhou Hang, Jie Liu, Jia-Pan Wang, Feng-Feng Li, Pei-Feng Li, Qing-Nan Kong, Jing Shi, Hong-Yu Ji, Zhi-Min Du, Jing Zhao (2023) - European journal of pharmacology
19. Protective effects of 7,8-dihydroxyflavone on retinal ganglion and RGC-5 cells against excitotoxic and oxidative stress.
    Vivek K Gupta, Yuyi You, Jonathan C Li, Alexander Klistorner, Stuart L Graham (2013) - Journal of molecular neuroscience : MN
20. R13 preserves motor performance in SOD1
    Xiao Li, Chongyang Chen, Xu Zhan, Binyao Li, Zaijun Zhang, Shupeng Li, Yongmei Xie, Xiangrong Song, Yuanyuan Shen, Jianjun Liu, Ping Liu, Gong-Ping Liu, Xifei Yang (2021) - Theranostics